All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your AML Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2019-03-05T09:59:33.000Z

EMA grants gilteritinib regulatory review for the treatment of patients with relapsed/refractory FLT3-positive acute myeloid leukemia

Mar 5, 2019
Share:

Bookmark this article

On 1 March 2019, the European Medicines Agency (EMA) accepted a marketing authorization application and granted regulatory review to gilteritinib, a potent, oral fms-like tyrosine kinase 3 (FLT3) inhibitor, for the treatment of adult patients with relapsed or refractory (R/R) FLT3-positive acute myeloid leukemia (AML).1 This comes after gilteritinib received FDA approval for the treatment of patients with FLT3-positive R/R AML in November 2018.

The marketing authorization application is based on the results from the randomized phase III ADMIRAL study (NCT02421939), which is assessing the efficacy of oral gilteritinib vs salvage chemotherapy in adult patients with FLT3-positive R/R AML. Interim results from the trial demonstrated a complete remission/complete remission with partial hematologic recovery rate of 21%.2 The results from the ADMIRAL trial are to be presented at the American Association for Cancer Research Annual Meeting 2019, Atlanta, USA, in March 2019.

According to the drug manufacturers, the marketing authorization application for gilteritinib to the EMA received accelerated assessment, which could result in a shorter timeframe for approval from the Committee for Medicinal Products for Human Use.

  1. Pharmafield. EMA accepts marketing authorization application for XOSPATA (gilteritinib). https://pharmafield.co.uk/pharma_news/ema-accepts-maa-for-xospatatm-gilteritinib/ [Accessed 2019 Mar 04]
  2. Perl A.E. et al. An open-label, randomized phase III study of gilteritinib versus salvage chemotherapy in relapsed or refractory FLT3 mutation-positive acute myeloid leukemia. J Clin Oncol. 35, 2017 (suppl; abstr #TPS7067). 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, 2017 June 2–6; Chicago, IL, USA.

Your opinion matters

Do you intend to implement next generation sequencing for measurable residual disease monitoring in AML patients?
0 votes - 6 days left ...

Newsletter

Subscribe to get the best content related to AML delivered to your inbox